AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2432555 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto burst pacing
Number of subjects: 32
Study 2432555 — intervention group
Group type: EXPERIMENTAL
Intervention: Random burst pacing
Number of subjects: 32
Study 2432555 — intervention group
Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 32
Study 31615996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose carbon monoxide exposure (100-200 ppm) for 12 weeks
Number of subjects: 38
Study 30360964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg subcutaneous every two weeks)
Number of subjects: 341
Study 30360964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg subcutaneous every four weeks)
Number of subjects: 341
Study 30360964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg Q2W)
Number of subjects: 341
Study 30360964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 27502810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan (TJQ) intervention (2/week for 16 weeks)
Number of subjects: 44
Study 27502810 — intervention group
Group type: COMPARATOR
Intervention: Educational course about FMS (Control Group) (2/week for 16 weeks)
Number of subjects: 44
Study 24452879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone prolonged-release (PR)
Number of subjects: 0
Study 24452879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone PR
Number of subjects: 0
Study 22582911 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) plus red light therapy
Number of subjects: 38
Study 22582911 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus red light therapy
Number of subjects: 38
Study 20974573 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily
Number of subjects: 0
Study 20974573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17155971 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine interval computed tomography (CT)
Number of subjects: 105
Study 15578800 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0
Study 15578800 — intervention group
Group type: EXPERIMENTAL
Intervention: N of 1 randomized controlled trials (RCTs)
Number of subjects: 0
Study 15578800 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic medicine
Number of subjects: 0
Study 11856461 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma (SDP)
Number of subjects: 67
Study 11856461 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 67
Study 9536834 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional management supplemented by regular measurements of static respiratory system compliance
Number of subjects: 245
Study 9536834 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical management (control group)
Number of subjects: 245
Study 9536834 — intervention group
Group type: COMPARATOR
Intervention: Control group survivors
Number of subjects: 245
Study 9536834 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group survivors
Number of subjects: 245
Study 7633189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mg kg‐1 day‐1 prednisolone for six months
Number of subjects: 41
Study 7633189 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 41
Study 1688515 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA (30 mg) in distilled water
Number of subjects: 8
Study 1688515 — intervention group
Group type: COMPARATOR
Intervention: ThioTEPA (30 mg) in 10% (v/v) Tween 80 (30 ml)
Number of subjects: 8
Study 28071 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg b.i.d.)
Number of subjects: 20
Study 28071 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg b.i.d.)
Number of subjects: 20
Study 30381466 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 1178
Study 30381466 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic messages
Number of subjects: 1178
Study 30381466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dashboard access
Number of subjects: 1178
Study 30381466 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 1178
Study 28135843 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention using ethyl glucuronide (EtG) biomarker
Number of subjects: 79
Study 28135843 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement only for study participation (Control)
Number of subjects: 79
Study 25484179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800-2400mg, once-daily
Number of subjects: 283
Study 25484179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 600-1800mg, once-daily
Number of subjects: 283
Study 25484179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 25484179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 900mg, once-daily (during recurrence prevention study)
Number of subjects: 283
Study 25484179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 300, 900, and 1800mg, once-daily (during recurrence prevention study)
Number of subjects: 283
Study 22689216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0
Study 22689216 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted Control Group
Number of subjects: 0
Study 21164424 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time <12 h
Number of subjects: 10464
Study 21164424 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time 12 to 24 h
Number of subjects: 10464
Study 21164424 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time >24 h
Number of subjects: 10464
Study 19217337 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 507
Study 19217337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 15785941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (Calcijex) administered as a bolus injection three times a week for up to 12 weeks, with initial doses of 0.5-1.5 microg based on severity of secondary HPT.
Number of subjects: 47
Study 15785941 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a week for up to 12 weeks.
Number of subjects: 47
Study 15785941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (Calcijex)
Number of subjects: 47
Study 15785941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12151929 — intervention group
Group type: EXPERIMENTAL
Intervention: TA 50 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30
Study 12151929 — intervention group
Group type: EXPERIMENTAL
Intervention: TA 100 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30
Study 12151929 — intervention group
Group type: EXPERIMENTAL
Intervention: TA 10 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30
Study 12151929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of previous studies with a 30‐min loading dose of 12.5 mg/kg and maintenance infusion of 6.5 mg x kg(‐1) x hr(‐1)
Number of subjects: 30
Study 12151929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of previous studies with a 30 mg/kg loading dose plus 16 mg x kg(‐1) x h(‐1) continuous infusion
Number of subjects: 30
Study 10412096 — intervention group
Group type: EXPERIMENTAL
Intervention: WHP intervention (multiple risk factor intervention targeting smoking, nutrition, and physical activity)
Number of subjects: 2055
Study 10412096 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2055
Study 7729044 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 62
Study 7729044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandralone
Number of subjects: 62
Study 7729044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 62
Study 7729044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2029831 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.250 mg
Number of subjects: 6
Study 2029831 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 6
Study 2029831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6265109 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (500 mg/m2 I.V.), Adriamycin (50 mg/m2 I.V.), DTIC (250 mg/m2 I.V.), and vincristine (1 mg/m2 I.V.) every 4 weeks for three cycles followed by the same combination every 4 weeks for an additional six cycles.
Number of subjects: 202
Study 6265109 — intervention group
Group type: COMPARATOR
Intervention: Non-cross-resistant drug combination of BCNU (100 mg/m2 I.V.), procarbazine (100 mg/m2 p.o. daily x 10 days), methotrexate (25 mg/m2 I.V.), and vinblastine (5 mg/m2 I.V.) every 4 weeks for six cycles.
Number of subjects: 202
Study 6265109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating treatments with the two regimens for a total of six cycles of therapy.
Number of subjects: 202
Study 31544471 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical intravenous vancomycin
Number of subjects: 6553
Study 31084291 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE (early intervention treatment model)
Number of subjects: 404
Study 31084291 — intervention group
Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 404
Study 28778815 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg/day for 14 days
Number of subjects: 80
Study 28778815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26372945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 25
Study 26372945 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 25
Study 23598371 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg candesartan in the first week, and 32 mg candesartan in the second and third week
Number of subjects: 40
Study 23598371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21860000 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + EPO
Number of subjects: 257
Study 21860000 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 257
Study 19469696 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 93
Study 19469696 — intervention group
Group type: COMPARATOR
Intervention: paliperidone ER
Number of subjects: 93
Study 19469696 — intervention group
Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 93
Study 17925885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 17925885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15514875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) combined with maxillary protraction
Number of subjects: 20
Study 15514875 — intervention group
Group type: COMPARATOR
Intervention: Maxillary protraction alone
Number of subjects: 20
Study 11683079 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a noseclip
Number of subjects: 13
Study 11683079 — intervention group
Group type: COMPARATOR
Intervention: Without wearing a noseclip
Number of subjects: 13
Study 9585306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 600
Study 9585306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.08 mg/kg
Number of subjects: 600
Study 9585306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg
Number of subjects: 600
Study 9585306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg/kg
Number of subjects: 600
Study 8029790 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (A)
Number of subjects: 0
Study 8029790 — intervention group
Group type: COMPARATOR
Intervention: Low intensity oral anticoagulation with warfarin (W)
Number of subjects: 0
Study 8029790 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment with warfarin and aspirin (WA)
Number of subjects: 0
Study 8029790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 8029790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (WA), Warfarin (W), Aspirin (A)
Number of subjects: 0
Study 2644695 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gravity drains
Number of subjects: 0
Study 2644695 — intervention group
Group type: COMPARATOR
Intervention: PVC drains (with vacuum suction)
Number of subjects: 0
Study 47417 — intervention group
Group type: EXPERIMENTAL
Intervention: RA27/3 (intranasally)
Number of subjects: 49
Study 47417 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV77.DE‐5
Number of subjects: 49
Study 47417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinees (combined)
Number of subjects: 49
Study 47417 — intervention group
Group type: COMPARATOR
Intervention: Naturally infected patients
Number of subjects: 49
Study 31079555 — intervention group
Group type: EXPERIMENTAL
Intervention: α-hydroxyisocaproic acid (α-HICA)
Number of subjects: 40
Study 31079555 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate free acid (HMB-FA)
Number of subjects: 40
Study 31079555 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium β-hydroxy-β-methylbutyrate (HMB-Ca)
Number of subjects: 40
Study 31079555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 40
Study 28434043 — intervention group
Group type: EXPERIMENTAL
Intervention: Early whole brain radiotherapy (WBRT) (45 Gy)
Number of subjects: 318
Study 28434043 — intervention group
Group type: COMPARATOR
Intervention: No early WBRT
Number of subjects: 318
Study 25414065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Laparoscopic Vision System (3D LVS)
Number of subjects: 24
Study 25414065 — intervention group
Group type: COMPARATOR
Intervention: Two-Dimensional Laparoscopic Vision System (2D LVS)
Number of subjects: 24
Study 23618425 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders (ComRem) with general implementation activities (GIA)
Number of subjects: 286
Study 23618425 — intervention group
Group type: COMPARATOR
Intervention: General implementation activities (GIA) only
Number of subjects: 286
Study 21668835 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% nicotinamide-phosphatidylcholine (N-PHCL) emulsion
Number of subjects: 0
Study 21668835 — intervention group
Group type: COMPARATOR
Intervention: 1% topical clindamycin phosphate
Number of subjects: 0
Study 19555037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (IL‐6) levels
Number of subjects: 68
Study 19555037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (TNF‐alpha) levels
Number of subjects: 68
Study 19555037 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated angioplasty
Number of subjects: 68
Study 19555037 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilation before stenting
Number of subjects: 68
Study 17004893 — intervention group
Group type: EXPERIMENTAL
Intervention: B. polyfermenticus tablets at a dose of 3.1 x 10(8) colony-forming units/day for 8 weeks
Number of subjects: 25
Study 17004893 — intervention group
Group type: EXPERIMENTAL
Intervention: B. polyfermenticus tablets
Number of subjects: 25
Study 17004893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12967736 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 132
Study 12967736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 10493339 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS (224 mmol/l)
Number of subjects: 738
Study 10493339 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/l)
Number of subjects: 738
Study 8719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 33
Study 8719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 33
Study 8719029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2066768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg oral dextroamphetamine
Number of subjects: 10
Study 2066768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6354828 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oral omeprazole
Number of subjects: 8
Study 6354828 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of oral omeprazole
Number of subjects: 8
Study 6354828 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of oral omeprazole
Number of subjects: 8
Study 6354828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30144099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vixotrigine (400 mg for men, 300 mg for women) administered orally twice daily for 36 days
Number of subjects: 60
Study 30144099 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally twice daily for 36 days
Number of subjects: 60
Study 28410367 — intervention group
Group type: EXPERIMENTAL
Intervention: NO‐charged catheters
Number of subjects: 12
Study 28410367 — intervention group
Group type: EXPERIMENTAL
Intervention: NO‐charged urinary catheters
Number of subjects: 12
Study 28410367 — intervention group
Group type: COMPARATOR
Intervention: Regular control catheters (CT‐group)
Number of subjects: 12
Study 25937157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife conization with lateral hemostatic sutures
Number of subjects: 102
Study 25937157 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conization without lateral hemostatic sutures
Number of subjects: 102
Study 24345329 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 28
Study 24345329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21986094 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. denosumab (120 mg) every 4 weeks
Number of subjects: 5723
Study 21986094 — intervention group
Group type: COMPARATOR
Intervention: i.v. zoledronic acid (4 mg) every 4 weeks
Number of subjects: 5723
Study 19995510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: bevelling the margins of buccal fissures (0.5 mm bevel) after enameloplasty
Number of subjects: 20
Study 19995510 — intervention group
Group type: COMPARATOR
Intervention: Group I: without bevel (standard procedure)
Number of subjects: 20
Study 18159148 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 101
Study 18159148 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily
Number of subjects: 101
Study 15528287 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐taped final year student doctor interviews
Number of subjects: 60
Study 15528287 — intervention group
Group type: COMPARATOR
Intervention: Previous experience of a real student doctor interview
Number of subjects: 60
Study 15528287 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child characteristics
Number of subjects: 60
Study 11345495 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsoft computer mouse with standard settings
Number of subjects: 12
Study 11770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback during acquisition
Number of subjects: 0
Study 11770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback during acquisition
Number of subjects: 0
Study 11770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined visual and auditory information
Number of subjects: 0
Study 11770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructing participants to attend to one information source
Number of subjects: 0
Study 11770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Error detection and correction processes
Number of subjects: 0
Study 9278661 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (46 Gy) and bolus 5-fluorouracil (30 min before six radiotherapy fractions)
Number of subjects: 136
Study 9278661 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery combined with postoperative radiotherapy and 5-fluorouracil
Number of subjects: 136
Study 9278661 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 136
Study 8340736 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg and calcium 1000 mg daily
Number of subjects: 54
Study 8340736 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1000 mg daily
Number of subjects: 54
Study 3089195 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) for three days before and during radiotherapy (five fractions of 400 rad [4 Gy] each)
Number of subjects: 20
Study 3089195 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) feeding recommenced 24 hours postoperatively via a feeding jejunostomy
Number of subjects: 20
Study 3089195 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED)
Number of subjects: 20
Study 29144103 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program including controlled breathing training, NMES superimposed onto voluntary muscular contraction for 8 weeks (2 h/week)
Number of subjects: 36
Study 29144103 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 36
Study 27617832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 103
Study 27617832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 103
Study 27617832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 103
Study 27617832 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 103
Study 27617832 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 103